Background
and/or overexpression is associated with multiple maligThe HER2 gene (also known as c-erbB2 and neu) is amplinancies [13] . fied and/or overexpressed in several human malignancies, including breast cancer [1] , and is linked with an increased
We showed previously that PEA3 is invariably overexpropensity of such tumors to metastasize, resulting in a pressed in mammary tumors of transgenic mice that expoor prognosis for the patient [2] . Increased expression press the wild-type rat neu cDNA under the transcriptional of HER2 in breast tumors is also correlated with a poor control of the MMTV promoter (MMTV-neu) [14] . PEA3 response to hormonal and chemotherapeutic agents [3] [4] [5] .
is similarly overexpressed in 76% of all human breast The HER2 gene encodes a receptor tyrosine kinase structumors; 93% of the HER2-positive subclass of such tuturally related to the epidermal growth factor receptor mors, which represent 20%-30% of all breast tumors [2] , family proteins, which act through downstream signaling overexpress PEA3 [15] . Here, we show that all three pea3 modules, including the Ras and phosphoinositide subfamily ets genes are coordinately upregulated in mam-3Ј-kinase pathways, to alter gene expression [1] .
mary epithelial tumor cells of MMTV-neu transgenic mice, but other ets genes, including those commonly exMouse pea3 (the human gene is named E1A-F and ETV4) pressed in the mouse mammary gland, are not. Interferis the founding member of the pea3 subfamily of ets genes, ence with PEA3 subfamily protein function in mammary which also include er81 (ETV1) and erm (ETV5) [6] [7] [8] [9] [10] [11] .
epithelial cells of MMTV-neu transgenic mice delayed Ets proteins share conserved winged helix-turn-helix the onset and progression of mammary tumors, suggesting ETS DNA binding domains comprising approximately a required role for these Ets proteins in oncogenesis. 85 amino acids [12] . These proteins bind to sequence elements bearing a centrally located conserved 5Ј-GGA,
Results
A/T-3Ј motif; the DNA binding specificity of individual
PEA3 is overexpressed in mouse mammary epithelial tumor cells
Ets proteins is dictated by sequences flanking this core.
Whereas PEA3 is overexpressed in mouse mammary tuCommonly, Ets proteins activate transcription, but some mors appearing in mice bearing the MMTV-neu transmembers of the family repress this process. Ets proteins play key roles in embryonic development; their mutation gene, the cellular expression profile of PEA3 in these tumors has not been assessed. To this end, we made use of mice bearing a mutation in the pea3 gene; such mice harbor a deletion in the pea3 gene, which is replaced by sequences representing an internal ribosome entry site and a nuclear localization signal linked to Escherichia coli ␤-galactosidase (nlslacZ) (Figure 1a ). This mutant pea3 allele (pea3 nlslacZ ) is nearly identical in structure to that described previously; it only differs from the latter by the presence of sequences encoding lacZ at the site of the deletion in the pea3 gene [16] . Mice homozygous for either pea3 loss-of-function allele are viable; males are sterile, but the reproductive capacity of females is normal [16] . The profile of lacZ expression (␤-galactosidase activity) in pea3 nlslacZ/ϩ mutant embryos and adults mimics that of the wild-type pea3 gene.
To assess the expression of the pea3 nlslacZ allele in mouse mammary tumors, we derived offspring from crosses between pea3 nlslacZ/ϩ mutant mice and MMTV-neu transgenic mice. The N#202 MMTV-neu transgenic strain, used throughout this study, bears the wild-type Neu cDNA. Mammary tumors arise in this transgenic strain due to deletions in sequences encoding the extracellular region of Neu [17] , resulting in constitutive dimerization and consequent activation of its tyrosine kinase activity [18] . We prepared mammary gland whole mounts from the transgenic pea3 nlslacZ/ϩ female mice bearing mammary tumors and incubated these with X-gal to detect ␤-galactosidase activity. Multiple distinct tumor masses expressing ␤-galactosidase were readily apparent (Figure 1b) . To examine the cellular expression profile of the mutant pea3 allele, we incubated mammary tumors from MMTV-neu transgenic mice bearing either wild-type or a mutant pea3 allele with X-gal and prepared serial sections. These sections were either stained with hematoxylin-eosin ( Figure  1c The pea3 subfamily genes are coordinately overexpressed in Neu-induced tumors
To determine whether ets genes other than pea3 are expressed in the mammary gland and overexpressed in neu transgenic mice. We prepared cDNA from the RNA mammary tumors, we compared the spectrum of Ets transamples, amplified these with pairs of degenerate oligonuscripts in RNA samples from two normal mammary glands cleotide primers complementary to ETS domain sequences, and cloned and sequenced 400 independent of virgin mice and from two mammary tumors of MMTV- PEA3 subfamily transcripts are increased in MMTV-neu-induced mammary tumors. (a) PEA3, ERM, and ER81 transcripts are expressed at low levels in the normal, virgin mouse mammary gland from either the FVB/N strain (FVB) or from asymptomatic MMTVneu transgenic mice (Tg) but are increased substantially in mammary tumors (T1-T6) that arose in the MMTV-neu transgenic mice. A multiplex RNase protection assay was performed using riboprobes specific to mouse PEA3, ERM, and ER81 mRNA; mouse rpL32 was used as an internal control for RNA loading. (b) The PEA3 subfamily transcripts are increased in the MMTV-neu tumor samples compared to the normal mammary gland controls from either the nontransgenic FVB/N strain (FVB) or from asymptomatic MMTVneu transgenic mice (Tg). Relative PEA3 subfamily transcript abundance was quantified by PhosphorImager analysis and was normalized to that of rpL32. The normalized abundance of each PEA3 subfamily transcript in the FVB/N samples was set to 1. (c) The abundance of Ets-1, Ets-2, and GABP-␣ mRNA levels is reduced in mammary tumors arising in the MMTV-neu transgenic mice. A multiplex RNase protection assay was performed using riboprobes specific to mouse Ets-1, Ets-2, and GABP-␣ mRNA; rpL32 was used as an internal control for RNA loading.
autoradiogram. (d) Quantification of the tissue relative to that of the internal control All the lanes in this panel were derived abundance of Ets-1, Ets-2, and GAPB-␣ transcript, rpL32. Transcript abundance was from the same exposure of the original transcripts in normal and mammary tumor quantified as described above.
cDNAs (92 or more cDNAs from each RNA source). We also examined the transcript levels of three other ets genes (ets-1, ets-2, and gabp-␣) in another set of similar PEA3, ER81, ERM, GABP-␣, Ets-1, Ets-2, Elf, and Tel samples (Figure 2c,d) . These three ets genes were excDNAs were readily isolated from all the samples. ER81 pressed at the same or greater levels than those of pea3, and ERM cDNAs were recovered at much higher freer81, and erm in the normal mammary gland samples. The quencies from the tumor samples than from the normal abundance of the Ets-1, Ets-2, and GABP-␣ transcripts samples, suggesting that er81 and erm were overexpressed were reduced in the tumor samples compared to the norin mammary tumors compared to normal mammary tissue mal mammary glands. The reduced expression of these (data not shown).
ets genes in the tumor samples may reflect their downregulation in epithelial tumor cells. Alternatively, these genes To investigate this potential, we compared PEA3, ER81, may normally be expressed in nonepithelial cells; their and ERM transcript levels in normal mammary gland apparent reduced expression in tumor tissue may reflect samples with those in several mammary tumor samples the reduced contribution of these stromal cells to the from MMTV-neu transgenic mice by multiplex ribotumor mass compared to the normal mammary gland. nuclease (RNase) protection analysis (Figure 2a,b) . All
Whatever the explanation, these data suggest that, among three PEA3 subfamily transcripts were coordinately overthe ets gene transcripts examined, those of the pea3 subexpressed in independent mammary tumors. The variafamily were selectively upregulated in Neu-induced tion in the extent of overexpression of these transcripts mouse mammary tumors. among the tumors may reflect the cellular heterogeneity of the tumors. Mammary tumors comprise principally epi- To ensure that ⌬NPEA3En functioned as expected, we assessed its capacity to affect reporter gene expression from two different PEA3-responsive reporters in transient transfection experiments. One reporter bears an artificial promoter comprising repeats of an optimal PEA3 binding site juxtaposed to a TATA box, whereas the other contains the urokinase plasminogen activator (uPA) enhancer/promoter. We assessed the capacity of ⌬NPEA3En to affect expression of luciferase from these reporters in mouse FM3A cells, which express high endogenous levels of PEA3 [6] . ⌬NPEA3En reduced expression of both reporters in a dose-dependent fashion in these cells ( Figure  3b ). We also assayed the capacity of ⌬NPEA3En to affect PEA3 subfamily-activated reporter gene expression in COS-1 cells, which do not express PEA3 at detectable levels [6] . ⌬NPEA3En suppressed PEA3-, ERM-, and ER81-activated luciferase expression in a dose-dependent fashion, suggesting that it can compromise the function of all three PEA3 subfamily proteins (Figure 3c ). Western immunoblotting experiments revealed that the doses of ⌬NPEA3En used in these experiments did not affect expression of PEA3, ERM, or ER81 from the pCANmyc vectors encoding these proteins ( Figure 3d ). ⌬NPEA3En cells. Different DNA doses (25-100 ng) of the pCANmyc vector encoding ⌬NPEA3En or the empty expression vector (pCANmyc) were transfected as described in the Materials and methods. (c) Dominant-negative PEA3 reduces the capacity of PEA3, ERM, and ER81 to activate luciferase expression from the 5xPEA3-luc reporter plasmid in COS-1 cells in a dose-dependent fashion. The pCANmyc expression vector was used to effect the expression of ⌬NPEA3En, PEA3, ERM, and ER81; the empty expression vector (pCANmyc) was also independently transfected in these experiments to serve as a control. Increasing doses (25-250 ng) of the appropriate expression vector were transfected as described in the Materials and methods. The basal luciferase activity resulting from transfection of the reporter plasmid with the empty expression vectors was set at 1. was specific in its ability to inhibit the function of the PEA3 subfamily proteins because it was unable to repress GAL4-VP16-mediated expression of luciferase from a GAL4-responsive luciferase reporter, which does not contain PEA3 binding sites (Figure 3e ). Western immunoblotting experiments showed that ⌬NPEA3En was expressed in a dose-dependent manner in these experiments (Figure 3f ) to levels equivalent to those required to nearly completely repress PEA3-, ERM-, or ER81-activated luciferase expression from the PEA3-responsive reporter in the same COS cells (Figure 3d,f) . These observations suggest that ⌬NPEA3En inhibited the function of the PEA3 subfamily proteins likely by competing for their binding sites in the PEA3-responsive promoter of the reporter.
To determine whether ⌬NPEA3En could similarly affect for this protein under the transcriptional control of the MMTV promoter and used the resulting DNA to derive independent transgenic founder strains. One transgenic strain, which expressed ⌬NPEA3En transcripts in organs (n ϭ 14) of the bitransgenic mice 2 months after the characteristic of the tissue specificity of the MMTV proprimary tumor was detected (Table 1) . By contrast, the moter, was used in subsequent experiments. The mambitransgenic strain developed multiple tumors far less fremary glands of both virgin and lactating female mice of quently: only 21% (n ϭ 14) of the mice developed two this strain expressed ⌬NPEA3 transcripts at high levels or more tumors during this time frame. We noted upon relative to other organs. Whole-mount analyses of the autopsy that the primary tumors in the bitransgenic mice mammary glands of the MMTV-⌬NPEA3En mice rewere generally smaller 2 months after they were initially vealed no obvious developmental abnormalities during detected than those in the MMTV-neu transgenic strain. postnatal mammary gland development. These mice nursed
To quantify this difference, we weighed the mammary their pups, and the pups grew at normal rates, suggesting tumors arising in each transgenic strain 2 months after that the expression of ⌬NPEA3En in the mammary gland they were first detected. The mean weight of tumors did not affect the function of this organ.
arising in the MMTV-neu strain was 3.0 g (n ϭ 13), whereas that of the tumors in the bitransgenic strain was To learn whether the expression of ⌬NPEA3En affected 1.8 g (n ϭ 14) ( Table 1) . Primary mammary tumors arising mammary oncogenesis, we monitored the time of the in the MMTV-neu strain metastasize to the lungs at high appearance of mammary tumors in nulliparous fefrequency [22] . However, we did not detect a statistically male offspring resulting from crosses between MMTVsignificant difference in the percentage of mice bearing ⌬NPEA3En and MMTV-neu transgenic mice. We comlung metastases 2 months after the primary tumors arose pared the time of onset of mammary tumors in the between the two transgenic strains (Table 1) . Collec-MMTV-neu/⌬NPEA3En bitransgenic mice with that in tively, these observations suggest that the expression of MMTV-neu transgenic mice (Figure 4) . Tumors occurred ⌬NPEA3En in the mammary glands of MMTV-neu transin 50% of the MMTV-neu transgenic mice by 315 days genic mice delayed the appearance of mammary tumors of age, but 575 days were required for tumors to appear and reduced their number and growth in individual mice. in 50% of the bitransgenic mice. This difference is statistically significant, as determined by the log-rank test (p Ͻ To determine whether Neu and ⌬NPEA3En transcripts 0.003). By the end of the experiment (700 days), approxiwere expressed in mammary tumors in the bitransgenic mately 75% of the mice in both cohorts developed mammice, we carried out RNase protection analysis ( Figure  mary tumors. 5a). Neu transcripts were generally overexpressed in mammary tumors compared to unaffected contralateral Multiple tumors arise in different mammary glands of the mammary glands from the same mice, in keeping with MMTV-neu transgenic mice [17] . Generally, additional previous findings [17, 22] . The incidence of transgene independent tumors appear and progress during the deletions leading to constitutive activation of Neu was 2-month period after the primary tumor is first detected by palpation. Two or more tumors were found in 71% the same in the MMTV-neu and the bitransgenic mice, The percentage of mammary tumor-bearing mice, which also to initial identification of a tumor. Mice were grouped into those possessed lung metastases, was determined by analyzing having a single mammary tumor (1) versus those having two or more multiple haematoxylin-and eosin-stained tissue sections of the lungs (Ն2) tumors. The difference is statistically significant (p ϭ 2 months after initial palpation of the mammary tumor. The number of 0.0039) as determined by the one-sided z test. metastatic lesions per lung was not assessed because these were c The weight of the earliest arising mammary tumor was measured.
too numerous to be accurately enumerated at this time. The difference between MMTV-neu and MMTV-neu/⌬NPEA3En
suggesting that expression of ⌬NPEA3 in the bitransgenic ner to repress transcription from a complex viral promoter bearing EBS in Neu-transformed mammary epithelial tumice did not affect this process (data not shown).
mor cells. Surprisingly, ⌬NPEA3En transcripts were not expressed or were expressed at much lower levels in the mammary
Discussion
The pea3 subfamily genes were coordinately overextumors compared to the normal contralateral mammary gland of the same mouse. Indeed, ⌬NPEA3En was only pressed in Neu-induced mouse mammary tumors. Three other ets genes, ets-1, ets-2, and gabp-␣, which are normally expressed in the mammary tumors from two of seven mice examined (T2 and T7) and then only at levels subexpressed in the mammary gland, were not overexpressed in mammary tumors, suggesting that upregulation of the stantially lower than those observed in the histologically normal mammary glands contralateral to the tumors. The pea3 subfamily genes was specific. The genes comprising the pea3 subfamily have an identical architecture, strongly fact that ⌬NPEA3En was not generally expressed in the mammary tumors strongly suggests that this protein intersuggesting that they arose from a common ancestral gene [25] . Hence, these genes may also share common profered with Neu-induced mammary oncogenesis. Like mammary tumors of MMTV-neu transgenic mice, those moter elements; Neu may regulate the activity of transcription factors that bind to these sites, thus accounting arising in the bitransgenic mice also overexpressed PEA3 compared to the normal control mammary tissue (data not for their coordinate overexpression in mammary tumors. This hypothesis is supported by the observation that inshown).
duction of the oncogenically activated Raf kinase, which is known to act downstream of Neu, leads to the upregThe core sequence (5Ј-GGA, A/T-3Ј) characteristic of Ets protein binding sites (EBS) is present in the MMTV ulation of pea3 transcripts in human mammary epithelial cells [26] . promoter [23] , and the Ets-protein, GABP-␣, can activate transcription from the MMTV promoter dependent on these sites [24] . Hence, it is formally possible that
The expression of dominant-negative PEA3 under the aegis of the MMTV promoter in mammary epithelial cells ⌬NPEA3En can bind to these sites when expressed at high levels and thereby repress neu transgene expression, delayed the onset of mammary tumors, reduced the number of such tumors in individual mice, and retarded the thus affecting mammary oncogenesis. To explore this potential, we used a mammary epithelial cell line (NDL) growth of these tumors in the bitransgenic strain. Tumors arising in the bitransgenic mice did not express the derived from a mammary tumor of an MMTV-neu transgenic mouse. The NDL cell line supported high-level MMTV-⌬NPEA3En transgene or expressed it at low levels. These observations are consistent with a requirement expression of an MMTV-luciferase reporter plasmid (Figure 5b) . Independent cotransfection of an expression vecfor one or another PEA3 subfamily Ets protein for Neumediated mammary oncogenesis. tor encoding either PEA3 or ⌬NPEA3En with the MMTV-luciferase reporter did not affect expression of luciferase under conditions in which both proteins were
The requirement to extinguish ⌬NPEA3En function in Neu-positive mammary epithelial cells to ensure their expressed to high levels in these cells (Figure 5b,c) . Hence, it seems unlikely that either PEA3 or ⌬NPEA3En progression to malignancy likely accounts for the delayed onset and the reduced size and incidence of multiple binds to the EBS in the MMTV promoter even when they are overexpressed. These experiments also illustrate tumors in the bitransgenic mice. We imagine that both the MMTV-neu and MMTV-⌬NPEA3En transgenes are that ⌬NPEA3En did not function in a nonselective man- may be due to the episodic reexpression of ⌬NPEA3En in mammary tumors between the time these tumors first arise and are palpable and the time of sacrifice of the mice 2 months later. It is noteworthy that the expression of transgenes is unstable [19, 27] .
It is formally possible that the effect of ⌬NPEA3En on Neu-mediated tumor progression in the bitransgenic mice resulted from the inhibition of transcription of the MMTV-neu transgene. ⌬NPEA3En may bind directly to EBS in the MMTV promoter and thereby inhibit neu transgene transcription or it may act indirectly to negatively affect expression of the neu transgene in bitransgenic mice. Such a model would require that the two MMTV transgenes respond differently to ⌬NPEA3En despite the fact that the same promoter regulates expression of each transgene in the same cell. Both the MMTV⌬NPEA3En and MMTV-neu transgenes were expressed in the normal contralateral glands of tumor-bearing bitransgenic mice and in the normal mammary glands of asymptomatic bitransgenic mice, suggesting that they can be coexpressed in mammary epithelial cells. Furthermore, we could not repress MMTV reporter gene expression by overexpression of ⌬NPEA3En, nor could we activate this reporter by expression of PEA3 in Neu-transformed mouse mammary tumor cells despite the occurrence of EBS in the MMTV promoter. Hence, we think it is unlikely that ⌬NPEA3En represses expression of the MMTV-neu transgene in mammary tumor cells and that this accounts for its effect on mammary oncogenesis.
(a) Expression of the MMTV-⌬NPEA3En transgene is reduced or
Recently, Xing et al. [28] reported that PEA3 suppresses formed phenotype of these tumor cell lines, and offered the prospect that PEA3 might prove efficacious either alone or in combination with other agents to combat HER2-positive human tumors. By contrast, in addition initially expressed in the epithelial cells of the origin to others, we have observed that PEA3, ERM, and ER81 of mammary tumors. Oncogenesis is likely initiated by are each capable of activating the expression of reporter mutations in the neu transgene in rare epithelial cells, but genes coupled to PEA3-responsive promoters, including the progression of these cells to full malignancy may be the human HER2 promoter in various cell types including retarded by ⌬NPEA3En. This barrier to tumor progresmammary epithelial tumor cells ( [6, 20, [29] [30] [31] ; this resion may be breached in rare epithelial cells expressing port). We have noted, however, that the expression of both transgenes by a genetic or an epigenetic mechanism these same reporter genes is inhibited when each of the that results in reduced ⌬NPEA3En expression and func-PEA3 subfamily proteins is expressed at high levels. We tion. The need to block ⌬NPEA3En expression in initisuspect that transcriptional squelching accounts for these ated tumor cells, a condition that is not required for tumors observations. These findings coupled with our previous to arise in the MMTV-neu transgenic strain, likely acobservations demonstrating increased PEA3 transcript counts for the long delay in time to progression and incilevels in both mouse [14] and human [15] HER2/Neudence of mammary tumors in the bitransgenic mice. The reduced size of mammary tumors in the bitransgenic strain positive mammary tumors and those reported herein the GAL4-VP16 expression vector, and the 5xGAL4-luc reporter plasmid strongly suggest that use of PEA3 as a therapeutic agent have been described previously [20] . The MMTV-luc reporter was conis contraindicated.
structed by isolating the luciferase gene from pGL3-Basic and cloning it into the MMTV-SV40 plasmid [22] . To generate MMTV-⌬NPEA3En/
Conclusions
SV40pA, the DNA encoding ⌬NPEA3En was isolated from pCANmyc/ ⌬NPEA3En and was cloned into the MMTV-SV40 plasmid. The sequence
We hypothesize that PEA3 subfamily function is required of the DNA primers and details concerning the construction of the expresfor Neu-mediated mammary oncogenesis. This hypothesion and reporter vectors are available from the authors upon request.
sis is consistent with the finding that PEA3 subfamily
The PEA3 riboprobe template encompasses nucleotides transcripts were overexpressed in nearly all HER2/Neuof mouse PEA3 cDNA cloned into pBluescriptIIKS. The plasmid was linearized with BamHI to generate an antisense PEA3 RNA probe using positive mammary tumors and with the observation that T3 RNA polymerase and was used to detect PEA3 and ⌬NPEA3En
abrogating PEA3 subfamily function in the mammary transcripts. The ERM riboprobe template encompasses nucleotides gland suppressed Neu-mediated mammary oncogenesis. Cell lines were cultured as described previously [6, 20] . Transient transfections were carried out using LipofectAMINE Reagent (Life Technoloand Wnt/␤-catenin pathways, which are dysregulated in normalized to the total protein concentration of the lysates, which were assessed using the Bradford assay kit (Bio-Rad). COS-1 cell transfec-
Materials and methods
tions and analyses of luciferase activity were performed similarly, except for the following modifications. A total of 1.25 ϫ 10 5 cells were seeded
DNA constructs
The pCANmyc expression vector (a gift from Dr. Paul Polakis) bears the the day prior to transfection, and 0.25 g 5xPEA3-luc reporter was human cytomegalovirus promoter upstream of sequences encoding an cotransfected with either 0.025 g pCANmyc/PEA3, 0.25 g pCANepitope endogenous to the c-Myc protein [33] . The molecular cloning myc/ERM, or 1 g pCANmyc/ER81. Similarly, 0.1 g 5xGAL4-luc reand expression of cDNAs downstream of the c-Myc epitope leads to porter and 0.25 g GAL4-VP16 effector plasmid were transfected into the synthesis of fusion proteins bearing this epitope at their amino termini.
COS-1 cells. Transient transfections of the mouse mammary epithelial PCANmyc/⌬NPEA3En was constructed by PCR amplification of se-NDL tumor cell line was carried out as described above after seeding quences encoding amino acids 334-480 of mouse PEA3 cDNA using 2.5 ϫ 10 5 cells per plate a day earlier; 0.5 g MMTV-luc reporter was the RSV-PEA3 expression plasmid [20] and the pSCDMSMenT plasmid used with varying amounts of the effector DNAs encoding PEA3 or (a gift from Dr. Ali Fattaey) bearing the Drosphila repression domain as ⌬NPEA3En. templates. pCANmyc/PEA3 was isolated by cloning full-length mouse PEA3 cDNA from pGEM7PEA3 into pCANmyc1. Full-length mouse ERM
Western immunoblotting
cDNA was isolated by RT-PCR using mouse mammary tumor RNA and Protein isolation from transfected cells and immunoblotting were perwas cloned into pCANmyc1. Full-length mouse ER81 cDNA was isolated formed essentially as described previously [20] . Total protein (40 g) by PCR of ER81 sequences from pBS/ER81 (a gift from Dr. Tom Jessell) from COS-1 cells and from NDL cells (100 g) was separated on a and was cloned into the pCANmyc1 expression vector to generate 10% SDS-polyacrylamide gel prior to transfer. Proteins was detected pCANmyc/ER81. The DNA sequence of all recombinant plasmids was using the anti-9E10 c-myc monoclonal antibody and goat anti-mouse determined to ensure that mutations were not introduced during PCR.
horseradish peroxidase-conjugated secondary antibody (KPL; 474-The 3xPEA3-luc reporter was constructed by isolating three of the four 1806), followed by incubation with Western Blot Chemiluminescence PEA3 binding sites from 4xPEA3-CAT [6] and cloning them into pGL3-Reagent Plus (NEN Life Science Products) and exposure to X-ray film Basic (Promega) to generate 3xPEA3-luc. The uPA-luc reporter plasmid was a gift from Dr. Craig Hauser [34] . The 5xPEA3-luc reporter plasmid, (Kodak Scientific Imaging). 
